

Mayo Clinic Laboratories invests in Pathology Asia Holdings and LifeStrands Genomics to expand precision medicine in APAC

September 24, 2026 | News

The strategic collaboration will broaden access to advanced diagnostics and genomic testing across Southeast Asia, Australia and New Zealand.



Mayo Clinic Laboratories and Pathology Asia Holdings have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo's global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics.

William Morice II, M.D., Ph.D., President and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.

Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics.

Mayo Clinic Laboratories and LifeStrands Genomics will work together to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia and New Zealand.

Applications will span the identification of genetic conditions, disease risk assessment, diagnosis and treatment planning, enabling healthcare providers to integrate clinically relevant genomic insights into more personalised patient care.

LifeStrands Genomics will operate as "LifeStrands in collaboration with Mayo Clinic Laboratories" in certain markets, reflecting the organisations' shared commitment to expanding access to advanced genomic testing and precision medicine across the region.

Together, the organisations will pursue joint scientific initiatives, education and thought leadership to support the integration of genomics into patient care.

“Healthcare providers across Southeast Asia, Australia and New Zealand are increasingly seeking advanced diagnostic solutions to guide patient care,” said Dr Morice.

“Our collaboration with PAH and LifeStrands Genomics reflects our commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. Through this collaboration, we are bringing advanced diagnostic capabilities closer to patients and equipping healthcare providers with the insights needed to deliver personalised care.”

“Mayo Clinic Laboratories’ investment marks an important milestone in our relationship and a strong foundation for the next phase of diagnostic innovation across the region,” said Christopher Ting, M.D., Founder and CEO of Pathology Asia Holdings.

“Combining Mayo Clinic Laboratories’ global clinical and scientific expertise with PAH’s regional diagnostic capabilities and network will enable us to broaden access to advanced testing and increase access to genomics and precision medicine capabilities across Southeast Asia, Australia and New Zealand.”